U.S., Feb. 1 -- ClinicalTrials.gov registry received information related to the study (NCT06803693) titled 'Efficacy and Safety of Pola-RCHP-X Vs Pola-RCHP in Untreated DLBCL' on Jan. 27.
Brief Summary: The purpose of this study is to compare the efficacy and safety of genotype-guided targeted agents in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola RCHP-X) versus Pola RCHP in Chinese patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Diffuse Large B-Cell Lymphoma
Intervention:
DRUG: Polatuzumab vedotin
Polatuzumab vedotin IV infusion will be administered as per the schedule specified in t...